Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma  Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,

Published byArnold Griffin Modified over 6 years ago

Similar presentations

Presentation on theme: "Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma  Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,"— Presentation transcript:

1 Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma  Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD, Tomoyuki Yokose, MD, PhD, Hiroyuki Ito, MD, PhD, Yohei Miyagi, MD, PhD, Tomohiko Matsuzaki, MD, Masashi Nagata, MD, Hideyuki Furumoto, MD, Teppei Nishii, MD, Kayoko Katayama, PhD, Kouzo Yamada, MD, PhD, Munetaka Masuda, MD, PhD  The Annals of Thoracic Surgery  Volume 102, Issue 6, Pages (December 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 No significant differences were found in (A) disease-free survival (p = 0.280) or (B) overall survival (p = 0.564) between patients with mutated (Mt, solid line) or wild-type (Wt, dotted line) epidermal growth factor receptor (EGFR). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 (A) The disease-free survival of pN1-N2 patients with exon deletion 19 (Ex19, dotted line) was significantly better (p = 0.001) than that of pN1-N2 patients with exon 21 L858R point mutation (Ex21, solid line). (B) The overall survival of pN1-N2 patients with Ex19 was better than that of pN1-N2 patients with Ex21, although this was not statistically significant (p = 0.123). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 The (A) disease-free interval and (B) median survival time of pN1 patients with exon deletion 19 (Ex19, dotted line) were significantly longer compared with those of pN1 patients with exon 21 L858R point mutation (Ex21, solid line; p = and p = 0.022, respectively). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 (A) The disease-free interval of pN2 patients with exon 19 deletion (Ex19, dotted line) was longer than that of pN2 patients with exon 21 L858R point mutation (Ex21, solid line), although this was not statistically significant (p = 0.109). (B) No significant difference was found in median survival time between pN2 patients with Ex19 and pN2 patients with Ex21 (p = 0.856). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma  Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,"

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Results of Coronary Artery Endarterectomy and Coronary Artery Bypass Grafting for Diffuse Coronary Artery Disease  Srikrishna Sirivella, MD, Isaac Gielchinsky,

Results of Coronary Artery Endarterectomy and Coronary Artery Bypass Grafting for Diffuse Coronary Artery Disease  Srikrishna Sirivella, MD, Isaac Gielchinsky,
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Thomas J. Birdas, MD, Richard P. M

Thomas J. Birdas, MD, Richard P. M
Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,

Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,
Complete Metabolic Response Is Not Uniformly Predictive of Complete Pathologic Response After Induction Therapy for Esophageal Cancer  Brendon M. Stiles,

Complete Metabolic Response Is Not Uniformly Predictive of Complete Pathologic Response After Induction Therapy for Esophageal Cancer  Brendon M. Stiles,
Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K

Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K
Constantin Stefanidis, MD, Albert M

Constantin Stefanidis, MD, Albert M
Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations  Tae Jung Kim, MD, PhD, Choon-Taek.

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations  Tae Jung Kim, MD, PhD, Choon-Taek.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Suspected Aerogenous Lung Metastases From Nasopharyngeal Cancer

Suspected Aerogenous Lung Metastases From Nasopharyngeal Cancer
Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases
The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis  Naoto Morimoto,

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis  Naoto Morimoto,
Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,
Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

Similar presentations

Ads by Google